Invivyd (IVVD) Change in Accured Expenses (2021 - 2025)
Invivyd (IVVD) reported Change in Accured Expenses of -$6.0 million for Q4 2025, up 62.49% on a YoY basis from -$3.7 million in Q4 2024, and up 75.77% quarter-over-quarter from -$24.8 million in Q3 2025.
Invivyd (IVVD) Change in Accured Expenses (2021 - 2025) Analysis & Trends
Invivyd has reported Change in Accured Expenses for 5 years, with the latest figure at -$6.0 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses rose 62.49% year-over-year to -$6.0 million; the trailing twelve-month figure through Dec 2025 stood at -$30.8 million (down 385487.5% YoY), and the FY2025 full-year result was -$30.8 million, down 385487.5% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at -$6.0 million, up from -$24.8 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $20.3 million in Q1 2022, with the low at -$30.1 million in Q4 2021.
- Historically, Change in Accured Expenses has averaged -$3.3 million across 5 years, with a median of -$3.0 million in 2023.
- The largest YoY upside for Change in Accured Expenses was 248.77% in 2024 against a maximum downside of 53669.23% in 2024.
- Invivyd's Change in Accured Expenses stood at -$30.1 million in 2021, then surged by 75.72% to -$7.3 million in 2022, then surged by 174.42% to $5.4 million in 2023, then plunged by 394.74% to -$16.0 million in 2024, then jumped by 62.49% to -$6.0 million in 2025.
- The last three Change in Accured Expenses figures came in at -$6.0 million (Q4 2025), -$24.8 million (Q3 2025), and $10.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | -6.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.02 Mn |
| Dec 31, 2025 | -6.02 Mn |
| Sep 30, 2025 | -24.83 Mn |
| Sep 30, 2025 | -24.83 Mn |
| Jun 30, 2025 | 10.01 Mn |
| Jun 30, 2025 | 10.01 Mn |
| Mar 31, 2025 | -10.01 Mn |
| Mar 31, 2025 | -10.01 Mn |
| Dec 31, 2024 | -16.04 Mn |
| Dec 31, 2024 | -16.04 Mn |
| Sep 30, 2024 | 16.05 Mn |
| Sep 30, 2024 | 16.05 Mn |
| Jun 30, 2024 | 6.95 Mn |
| Jun 30, 2024 | 6.95 Mn |
| Mar 31, 2024 | -6.96 Mn |
| Mar 31, 2024 | -6.96 Mn |
| Dec 31, 2023 | 5.44 Mn |
| Dec 31, 2023 | 5.44 Mn |
| Sep 30, 2023 | -10.79 Mn |
| Sep 30, 2023 | -10.79 Mn |